1 Department of Cardiothoracic and Vascular Surgery, Medical Center of the Johannes Gutenberg-University Mainz, Germany.
2 Department of Vascular Surgery, University Hospital of Lausanne, Switzerland.
J Endovasc Ther. 2018 Apr;25(2):209-219. doi: 10.1177/1526602817752147. Epub 2018 Jan 9.
To investigate the outcomes of patients who were treated for thoracoabdominal aortic aneurysms (TAAAs) using custom-made fenestrated-branched stent-grafts.
A consecutive series of 108 patients (mean age 73.5 years; 73 men) with TAAA were treated with E-xtra Design Engineering customized fenestrated-branched stent-grafts between November 2011 and January 2017. Data on baseline characteristics, procedures, and clinical follow-up were collected from 6 regional European surgical centers for retrospective analysis of endoleaks, reinterventions, and target vessel patency. The median aneurysm diameter was 6.75 cm (range 5.5-13). The distribution of the TAAA according to the modified Crawford classification of extent was 25 (24%) type I, 19 (17%) type II, 20 (18%) type III, 29 (27%) type IV, and 15 (14%) type V.
Technical success was achieved in 95% (103/108) of cases. Major early perioperative complications occurred in 40 (37%) patients. The 30-day mortality was 9.2% (10/108), and perioperative spinal cord ischemia was observed in 6 (5.5%) patients [2 (1.8%) permanent]. During the mean follow-up of 17.6 months (range 3-52), 28 (26%) patients required late reintervention. Two patients died due to aneurysm- or procedure-related causes. The estimated survival rates at 1, 2, and 4 years were 87%, 84%, and 51%, respectively. The estimated target vessel patency rates at the same time points were 95%, 91%, and 90%, respectively. The freedom from reintervention estimates were 84% and 73% at 1 and 4 years, respectively.
Endovascular repair of TAAA using Jotec customized fenestrated-branched stent-grafts appears to be safe and effective in the early to midterm. The considerable rate of secondary interventions indicates that further improvements, graft surveillance, and follow-up are required.
研究使用定制开窗分支支架治疗胸主动脉夹层瘤(TAAA)患者的结局。
2011 年 11 月至 2017 年 1 月,6 个欧洲外科中心连续收治了 108 例 TAAA 患者(平均年龄 73.5 岁,73 名男性),采用 E-xtra Design Engineering 定制开窗分支支架进行治疗。收集基线特征、手术和临床随访资料,回顾性分析内漏、再次干预和靶血管通畅情况。中位动脉瘤直径为 6.75cm(范围 5.5-13)。根据改良 Crawford 分类法,TAAA 的分布为 25 例(24%)I 型、19 例(17%)II 型、20 例(18%)III 型、29 例(27%)IV 型和 15 例(14%)V 型。
95%(103/108)的病例技术上获得成功。40 例(37%)患者发生主要早期围手术期并发症。30 天死亡率为 9.2%(10/108),6 例(5.5%)患者发生围手术期脊髓缺血[2 例(1.8%)永久性]。在平均 17.6 个月(3-52 个月)的随访期间,28 例(26%)患者需要晚期再次干预。2 例患者因动脉瘤或手术相关原因死亡。1、2、4 年的估计生存率分别为 87%、84%和 51%。相应的靶血管通畅率分别为 95%、91%和 90%。1 年和 4 年的无再干预估计率分别为 84%和 73%。
使用 Jotec 定制开窗分支支架治疗 TAAA 在早期至中期似乎是安全有效的。较高的二次干预率表明需要进一步改进、移植物监测和随访。